Published in Hypertension on October 04, 2010
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J (2014) 2.60
Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol (2012) 1.25
Endothelin, kidney disease, and hypertension. Hypertension (2013) 0.97
Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion. BMC Nephrol (2012) 0.96
Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). Medicine (Baltimore) (2014) 0.96
Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J (2011) 0.95
Endothelin. Pharmacol Rev (2016) 0.95
Role of the kidneys in resistant hypertension. Int J Hypertens (2011) 0.93
Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens (2011) 0.89
Key advances in antihypertensive treatment. Nat Rev Cardiol (2012) 0.84
Renal denervation after Symplicity HTN-3: an update. Curr Hypertens Rep (2014) 0.83
Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens (2010) 0.82
A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence. J Gen Intern Med (2017) 0.81
New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon? Curr Hypertens Rep (2015) 0.78
Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening. Heart Fail Rev (2014) 0.77
DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension (2010) 0.77
2013 Dahl Lecture: American Heart Association council for high blood pressure research clarifying the physiology of endothelin. Hypertension (2014) 0.77
Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome. J Pharmacol Exp Ther (2014) 0.76
Endothelin, sex, and pregnancy: unique considerations for blood pressure control in females. Am J Physiol Regul Integr Comp Physiol (2016) 0.75
Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine. PLoS One (2016) 0.75
Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials. Eur J Clin Pharmacol (2016) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell (2008) 7.68
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (2007) 6.88
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Circulating microRNAs in patients with coronary artery disease. Circ Res (2010) 6.28
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
The prognostic value of a nomogram for exercise capacity in women. N Engl J Med (2005) 5.03
B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med (2010) 4.42
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Targets and dynamics of promoter DNA methylation during early mouse development. Nat Genet (2010) 4.27
Exercise capacity and the risk of death in women: the St James Women Take Heart Project. Circulation (2003) 4.19
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44
Systolic pressure is all that matters. Lancet (2008) 3.42
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27
Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. Endocr Pract (2012) 3.27
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med (2009) 2.97
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94
Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens (2014) 2.82
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm (2012) 2.60
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51
Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation (2007) 2.50
Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens (2010) 2.49
Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med (2009) 2.48
Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension (2008) 2.44
Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) (2005) 2.35
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ (2012) 2.23
Renal denervation in moderate to severe CKD. J Am Soc Nephrol (2012) 2.21
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med (2007) 2.20
B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med (2009) 2.18
Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension (2012) 2.17
Methylated DNA immunoprecipitation (MeDIP). Methods Mol Biol (2009) 2.17
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension (2008) 2.09
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med (2003) 2.09
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation (2012) 2.07
Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil (2011) 2.05
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc Res (2006) 2.00
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA (2006) 2.00
Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome. Int Orthop (2014) 1.98
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail (2005) 1.96
Heart rate response to exercise stress testing in asymptomatic women: the st. James women take heart project. Circulation (2010) 1.93
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res (2009) 1.93
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA (2007) 1.91
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens (2004) 1.90
Clinical service organisation for heart failure. Cochrane Database Syst Rev (2012) 1.90
High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. J Hypertens (2002) 1.89
OpenSPIM: an open-access light-sheet microscopy platform. Nat Methods (2013) 1.88
Multilayer mounting enables long-term imaging of zebrafish development in a light sheet microscope. Development (2012) 1.87
A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol (2008) 1.85
Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation (2003) 1.84